Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Evolus stock
Learn how to easily invest in Evolus stock.
Evolus Inc is a drug manufacturers-specialty & generic business based in the US. Evolus shares (EOLS) are listed on the NASDAQ and all prices are listed in US Dollars. Evolus employs 174 staff and has a trailing 12-month revenue of around $132.4 million.
How to buy shares in Evolus
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – EOLS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Evolus stock price (NASDAQ: EOLS)Use our graph to track the performance of EOLS stocks over time.
Evolus shares at a glance
|Latest market close||$8.80|
|52-week range||$5.06 - $14.34|
|50-day moving average||$9.87|
|200-day moving average||$10.09|
|Wall St. target price||$16.38|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.30|
Buy Evolus shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Evolus stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Evolus price performance over time
|1 week (2022-09-29)||13.40%|
|1 month (2022-09-06)||-2.22%|
|3 months (2022-07-06)||-31.84%|
|6 months (2022-04-06)||-24.46%|
|1 year (2021-10-06)||23.94%|
|2 years (2020-10-06)||98.20%|
|3 years (2019-10-04)||15.01|
|5 years (2017-10-02)||N/A|
|Revenue TTM||$132.4 million|
|Gross profit TTM||$56.1 million|
|Return on assets TTM||-18.18%|
|Return on equity TTM||-102.72%|
|Market capitalisation||$473.4 million|
TTM: trailing 12 months
Evolus share dividends
We're not expecting Evolus to pay a dividend over the next 12 months.
Evolus share price volatility
Over the last 12 months, Evolus's shares have ranged in value from as little as $5.061 up to $14.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evolus's is 1.9959. This would suggest that Evolus's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Evolus, Inc. , a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California. .
Evolus in the news
Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain
Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022
13 Stocks to Sell Now According to Billionaire Larry Robbins
Frequently asked questionsWhat percentage of Evolus is owned by insiders or institutions?
Currently 33.284% of Evolus shares are held by insiders and 48.916% by institutions. How many people work for Evolus?
Latest data suggests 174 work at Evolus. When does the fiscal year end for Evolus?
Evolus's fiscal year ends in December. Where is Evolus based?
Evolus's address is: 520 Newport Center Drive, Newport Beach, CA, United States, 92660 What is Evolus's ISIN number?
Evolus's international securities identification number is: US30052C1071 What is Evolus's CUSIP number?
Evolus's Committee on Uniform Securities Identification Procedures number is: 30052C107
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert